Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue
Total revenue	$ 154,344	$ 98,382	$ 85,071
Operating expenses
Cost of revenue	49,301	22,530	22,274
Research and development	142,343	116,072	70,705
Sales and marketing	95,465	61,358	38,453
General and administrative	74,502	49,536	30,332
Amortization of intangible assets	1,699	1,703	1,698
Total operating expenses	363,310	251,199	163,462
Loss from operations	(208,966)	(152,817)	(78,391)
Interest and other income, net	1,668	6,590	9,785
Net loss	(207,298)	(146,227)	(68,606)
Add: Net loss attributable to noncontrolling interest	19
Net loss attributable to Adaptive Biotechnologies Corporation	(207,279)	(146,227)	(68,606)
Fair value adjustment to Series E-1 convertible preferred stock options			(964)
Net loss attributable to Adaptive Biotechnologies Corporation common shareholders	$ (207,279)	$ (146,227)	$ (69,570)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	$ (1.48)	$ (1.11)	$ (1.01)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	140,354,915	131,216,468	69,165,315
Sequencing Revenue
Revenue
Total revenue	$ 78,896	$ 41,439	$ 43,519
Development Revenue
Revenue
Total revenue	$ 75,448	$ 56,943	$ 41,552